{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:33:00Z","timestamp":1792740780304,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.vaccine.2009.04.065","type":"journal-article","created":{"date-parts":[[2009,5,22]],"date-time":"2009-05-22T07:31:47Z","timestamp":1242977507000},"page":"B112-B116","source":"Crossref","is-referenced-by-count":171,"special_numbering":"S2","title":["Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Carl E.","family":"Frasch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.04.065_bib1","series-title":"Bacterial Vaccines","first-page":"123","article-title":"Production and control of Neisseria meningitidis vaccines","author":"Frasch","year":"1990"},{"issue":"9157","key":"10.1016\/j.vaccine.2009.04.065_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(98)00279-7","article-title":"Uncloaking the meningococcus: dynamics of carriage and disease","volume":"353","author":"Stephens","year":"1999","journal-title":"Lancet"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2009.04.065_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","article-title":"Development of natural immunity to Neisseria meningitidis","volume":"19","author":"Pollard","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.065_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1084\/jem.17.5.553","article-title":"The results of the serum treatment in thirteen hundred cases of epidemic meningitis","volume":"17","author":"Flexner","year":"1913","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.065_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.147.3.629","article-title":"Protection against group b meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model","volume":"147","author":"Frasch","year":"1978","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2009.04.065_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","article-title":"Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era","volume":"21","author":"Trotter","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/IAI.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","author":"Vann","year":"1976","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","author":"Guirguis","year":"1985","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2009.04.065_bib11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.vaccine.2004.07.042","article-title":"Naturally-acquired immunity to Neisseria meningitidis group A","volume":"23","author":"Amir","year":"2005","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.065_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/315352","article-title":"Lack of immunity in university students before an outbreak of serogroup C meningococcal infection","volume":"181","author":"Jones","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.065_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2009.04.065_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"New Eng J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.065_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3181\/00379727-153-39563","article-title":"Clinical and laboratory investigations of monovalent and combined meningococcal polysaccharide vaccines","volume":"153","author":"Weibel","year":"1976","journal-title":"Proc Soc Exp Biol Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2009.04.065_bib17","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.065_bib18","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.065_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.065_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.065_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.065_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"issue":"9431","key":"10.1016\/j.vaccine.2009.04.065_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.065_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/505077","article-title":"Effectiveness analysis may underestimate protection of infants after group C meningococcal immunization","volume":"194","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.04.065_bib25","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization. MMWR 2005; 54(RR-7), 1\u201321."},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.065_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediat Adolesc Med"},{"issue":"8827","key":"10.1016\/j.vaccine.2009.04.065_bib27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo Brazil","volume":"340","author":"De Moraes","year":"1992","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.065_bib28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique Chile","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2009.04.065_bib29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2009.04.065_bib30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/CVI.00167-07","article-title":"Immunogenicity, reactogenicity, and safety of a P1.7b, 4 strain-specific serogroup B meningococcal vaccine given to preteens","volume":"14","author":"Hosking","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.065_bib31","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.065_bib32","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.065_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.065_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.065_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being mis-led?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.065_bib36","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.065_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","article-title":"considerations in the evaluatrion of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop","volume":"22","author":"De Gruttola","year":"2001","journal-title":"Controlled Clin Trials"},{"issue":"23","key":"10.1016\/j.vaccine.2009.04.065_bib38","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T12:38:48Z","timestamp":1589805528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":38,"alternative-id":["S0264410X09006197"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}